One of the major hurdles while trying to develop a biologic, including anti-amyloid and anti-tau therapies for AD, is low brain bioavailability of the biologic due to the blood-brain barrier (BBB) [3]. The gene discussed is MAPT; the disease is Alzheimer disease.